Form 4: Apellis Pharmaceuticals Chief People Officer Receives Significant Equity Grant

Kelley Boucher, Chief People Officer of Apellis Pharmaceuticals, Inc., was granted 45,095 Restricted Stock Units and 67,396 stock options, aligning her interests with long-term shareholder value.

Summary

• Kelley Boucher, Chief People Officer of Apellis Pharmaceuticals, Inc. (APLS), was granted 45,095 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 9, 2025.
• These RSUs were granted at a price of $0 and will vest annually over a four-year period, subject to continued service.
• Additionally, Ms. Boucher received a stock option award for 67,396 shares with an exercise price of $19.39, also granted on June 9, 2025.
• The stock options will vest over a four-year period, with 25% vesting one year from the grant date and the remaining 75% vesting monthly thereafter, subject to continued service.
• Following these transactions, Ms. Boucher beneficially owns 67,182 shares of Common Stock and 67,396 stock options.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates the company is actively incentivizing and retaining key management through standard equity compensation, which aligns executive interests with shareholder value. There are no negative financial implications beyond potential future dilution, which is a common aspect of such programs.

Positives

• The grant of Restricted Stock Units and stock options to the Chief People Officer aligns executive compensation with the long-term performance and shareholder value of Apellis Pharmaceuticals.
• Equity awards with multi-year vesting schedules incentivize key management personnel to remain with the company and contribute to its sustained growth.
• The $0 price for RSUs and the exercise price for options indicate a direct incentive tied to future stock price appreciation.

Negatives

• The issuance of new equity awards, particularly stock options and RSUs, can lead to potential future dilution for existing shareholders as these awards vest and are exercised.

Risks

• The value of the equity awards is subject to the future performance of Apellis Pharmaceuticals' stock price, meaning the actual realized value for the recipient could be lower than the current market value if the stock declines.
• The vesting conditions tied to continued service mean that the full benefit of these awards is contingent on Ms. Boucher remaining employed by the company for the entire four-year vesting period.

Future Outlook

The equity awards are structured to incentivize long-term performance, with vesting periods extending over four years, indicating an expectation of continued service and contribution from the Chief People Officer towards the company's future success.

Management Comments

• "This represents an award of Restricted Stock Units granted June 9, 2025, that vests annually from grant date over a four-year period subject to continued service."
• "This represents a stock option award granted June 9, 2025 that vests over a four-year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service."

Industry Context

Equity compensation, including Restricted Stock Units (RSUs) and stock options, is a standard practice in the biotechnology and pharmaceutical industries. It is widely used to attract, retain, and motivate key executives and employees, aligning their financial interests with the long-term growth and success of the company. This practice is particularly prevalent in growth-oriented sectors like biotech, where long development cycles and significant R&D investments necessitate long-term commitment from leadership.

Comparison to Industry Standards

• The use of a combination of RSUs and stock options for executive compensation is a common practice across the biotech and broader technology sectors, similar to compensation structures seen at companies like Moderna, BioNTech, or Regeneron Pharmaceuticals.
• A four-year vesting schedule is typical for executive equity grants, providing a balance between immediate incentive and long-term retention, consistent with industry benchmarks.
• The grant of RSUs at a $0 price is standard for such awards, representing a direct share grant that gains value as the company's stock price increases.
• The exercise price for stock options being set at the market price on the grant date (implied by the lack of mention of a discount) is also a standard practice, ensuring that the options only become valuable if the stock price appreciates from the grant date.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of equity awards from Apellis Pharmaceuticals, Inc. to Kelley Boucher, its Chief People Officer, which constitutes a related party transaction as it is between the company and a member of its executive management.

Stakeholder Impact

• Shareholders: Potential for future dilution as RSUs vest and options are exercised, but also benefit from increased alignment of executive interests with long-term company performance and value creation.
• Employees: May signal a stable and incentivized leadership team, potentially boosting morale and confidence in the company's direction.
• Management: Directly benefits from the equity awards, providing a significant incentive for continued service and performance.

Next Steps

• The granted Restricted Stock Units will vest annually over a four-year period from June 9, 2025, subject to continued service.
• The granted stock options will vest over a four-year period, with 25% vesting one year from June 9, 2025, and the remaining 75% vesting monthly thereafter, subject to continued service.

Key Dates

Keywords

Apellis Pharmaceuticals, APLS, SEC Form 4, insider transaction, equity grant, Restricted Stock Units, RSUs, stock options, executive compensation, Chief People Officer, Kelley Boucher, beneficial ownership